The Outlook for Controlled Substances in 2025
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
The Outlook for Controlled Substances in 2025
-
Narrado por:
-
De:
Acerca de esta escucha
On this episode of Ropes & Gray’s podcast series Controlling Opinions, life sciences regulatory and compliance partner Josh Oyster and counsel Beth Weinman are joined by health care partner Brett Friedman and litigation and enforcement partner Andrew O’Connor to discuss what’s to come in 2025 under the new Trump administration on key issues relating to controlled substances. The discussion covers:
- The DEA’s potential rescheduling of cannabis and the ongoing administrative hearing process.
- Updates on telemedicine flexibilities for prescribing controlled substances, including new rules and proposed regulations.
- Latest enforcement developments from the DOJ related to controlled substance prescribing via telemedicine, including notable cases and implications for the future.
Tune in for an insightful conversation on these critical topics and stay informed about the latest legal and regulatory changes in the life sciences and health care industries.
Todavía no hay opiniones